



Sponsors



Diamond



THE **EPILEPSY** COMPANY®

Platinum



Gold



Silver



Bronze



Supporters

Neurological Sciences
Foundation of Canada
• CNS - Don Paty Fund

Actelion

EMD Serono

Rx&D

The Canadian Neurological Sciences Federation is pleased to recognize those Sponsors who, as of April 15, 2012, have committed to supporting the 2012 Congress.

If you and your organization would like more information, or would like to discuss how you can partner with CNSF and meaningfully connect with our Congress delegates, please call or email Brett Windle, Corporate Development Coordinator at (403) 229-9544 or brett-windle@cnsfederation.org.

EDITORIALS

- 263** Iron - Too Much of a Good Thing
Mandar S. Jog, Derek B. Debicki
- 265** Clinical fMRI: A Pre-Surgical Test in Patients with Medically Intractable Epilepsy
Zheng Wang, Seyed M. Mirsattari
- 267** Amplitude-Integrated Electroencephalography: A Runaway Horse?
Kevin C. Dysart, Haresh M. Kirpalani, Courtney J. Wusthoff, Shashi S. Seshia
- 269** Neurocysticercosis: A Foreign Parasite Looking for "Permanent Resident" Status?
Jorge G. Burneo

REVIEW ARTICLES

- 271** Functional MRI Applications in Epilepsy Surgery
Craig A. Beers, Paolo Federico
- 286** Amyloid and Alzheimer's Disease: Inside and Out
Joshua H.K. Tam, Stephen H. Pasternak

HISTORICAL REVIEW

- 299** Dynamic Radiosurgery at the Toronto - Bayview Regional Cancer Centre, 1988-2007
P. Davey, M. Schwartz, P. O'Brien, B. Gillies

ORIGINAL ARTICLES

- 304** Clinical Overlap between Jakob-Creutzfeldt Disease and Lewy Body Disease
Maria Carmela Tartaglia, David Y. Johnson, Julie Ngoc Thai, Tatiana Cattaruzza, Katherine Wong, Paul Garcia, Stephen J. DeArmond, Bruce L. Miller, Michael D. Geschwind
- 311** Brain Region Specific Monoamine and Oxidative Changes During Restraint Stress
Ausaf Ahmad, Naila Rasheed, Ghulam Md Ashraf, Rajnish Kumar, Naheed Banu, Farah Khan, Muneera Al-Sheeha, Gautam Palit

- 319** A Review of Cases of Human Cysticercosis in Canada
Oscar H. Del Brutto
- 323** Magnesium as an Effective Adjunct Therapy for Drug Resistant Seizures
Peter A. Abdelmalik, Nina Politzer, Peter L. Carlen
- 328** Epileptiform Activity in Neurocritical Care Patients
Andreas H. Kramer, Nathalie Jette, Neelan Pillay, Paolo Federico, David A. Zygun
- 338** Carotid Artery Angioplasty and Stenting for Patients Less than 70 Years-of-Age
Ryan Alkins, Charles C. Matouk, Juan P. Cruz, Thomas Marotta, Walter Montanera, Julian Spears
- 343** NASCET Percent Stenosis Semi-Automated Versus Manual Measurement on CTA
Kevin Lian, Jeremy H. White, Eric S. Bartlett, Aditya Bharatha, Richard I. Aviv, Allan J. Fox, Sean P. Symons
- 347** Conus Medullaris Syndrome as a Complication of Radioisotope Cisternography
Bek-San Park, Jinse Park, Seong-Ho Koh, Hojin Choi, Hyun-Jeung Yu, Koo-Eun Lee, Young Joo Lee, Kyu-Yong Lee
- 352** MS Patients Report Excellent Compliance with Oral Prednisone for Acute Relapses
Sarah A. Morrow, Lynn McEwan, Katayoun Alikhani, Christopher Hyson, Marcelo Kremenchtzky
- 355** The Impact of Amplitude-Integrated Electroencephalography on NICU Practice
Juan Pablo Appendino, Patrick J. McNamara, Matthew Keyzers, Derek Stephens, Cecil D. Hahn
- 361** Concussion Knowledge among Medical Students and Neurology/Neurosurgery Residents
Miranda Boggild, Charles H. Tator
- 369** Pediatric Neurology Training in Canada: Current Status and Future Directions
Asif Doja

CLINICAL NEUROPATHOLOGICAL CONFERENCE

- 378** Multiple Cerebral Infarcts in Patient with Moyamoya Disease
C.S. Casserly, A. Salmon, D.A. Ramsay, D.M. Pelz, S.P. Lownie, M.J. Strong

NEUROIMAGING HIGHLIGHTS

- 383** Hyperperfusion Secondary to Middle Cerebral Artery Stenting
Zhen-Ni Guo, Ge Yang, Hong-Liang Zhang, Shou-Chun Wang, Yi Yang
- 385** Iniencephaly in an Adult Patient
Martin Côté, André Turmel, Karine Michaud, Pascale Lavoie, Jacques Francoeur, Claude Picard

BRIEF COMMUNICATIONS

- 388** Spinal CSF Leaks: Mimicker of Primary Headache Disorder in a Child
Sheri Harder, Robert W. Griebel, Edmond G. Lemire, Stefan Kriegler, Josh Gitlin, Shashi S. Seshia
- 393** Delayed Restricted Diffusion in Carbon Monoxide Leukoencephalopathy
Madeleine E. Sharp, Jason B. Chew, Manraj K.S. Heran, Jacqueline A. Pettersen
- 395** A Novel *PANK2* Gene Mutation with Sudden-Onset Dystonia
JiSun Kim, Hyeun Shin, Jinyoung Youn, Chang-Seok Ki, Ah Ra Cho, Jin Whan Cho

LETTERS TO THE EDITOR

- 398** To the Editor - Isolated Dysphagia after a Small Posterolateral Medullary Infarct: A Case Report
Ramin Zand, Kartheek Ganta, Mansour Afshani
- 400** To the Editor - RE: Neuroscience in Nazi Europe Part I: Eugenics, Human Experimentation, and Mass Murder. *Can J Neurol Sci.* 2011; 38:696-703
Lawrence A. Zeidman
- 400** To the Editor - Lumbar Radiculopathy-Mimicking Cortical Infarction of the Precentral Region
Yoon Jung Jang, Suk Yun Kang, Young-Min Lim, Seok-Beom Kwon, San Jung, Sung Hee Hwang
- 402** To the Editor - Cognitive and Mood Profile of Sturge-Weber Syndrome Affecting the Thalamus
Anish N. Kapadia, Neil P. Naik, R. Loch Macdonald, Tom A. Schweizer
- 405** To the Editor - Is the Treatment of Multiple Sclerosis Headed in the Wrong Direction?
Michael A. Kadoch

406 BOOKS RECEIVED/BOOKS REVIEWED

A-10 BOARD OF DIRECTORS/COMMITTEE CHAIRS

- A-11** Information for Authors
- A-12** Advertisers Index
- A-21** Classified Ads
- A-22** Classified Ads
- IFC** CNSF Sponsors
- IBC** 2012 CNSF Congress Agenda

For patients suffering from Chronic Migraine, consider BOTOX®.

NEW INDICATION

BOTOX® (onabotulinumtoxinA) is NOW indicated for the prophylaxis of headaches in adults with Chronic Migraine (≥15 days per month with headache lasting 4 hours a day or longer).¹

For more information visit www.BOTOX.ca and enter the password **CMBOTOX**

BOTOX® is contraindicated in: patients who are hypersensitive to botulinum toxin type A or to any ingredient in the formulation or component of the container; the presence of infection at the proposed injection site(s).¹

The term "Allergan unit" upon which dosing is based is a specific measurement of toxin activity that is unique to Allergan's formulation of botulinum toxin type A. Therefore, the "Allergan units" used to describe BOTOX® activity are different from those used to describe that of other botulinum toxin preparations and the units representing BOTOX® activity are not interchangeable with other products.¹

The safety and effectiveness of BOTOX® in the prophylaxis of headaches in Chronic Migraine has not been investigated in children and adolescents under 18 years of age or adults over 65 years of age.¹

No efficacy has been shown for BOTOX® in the prophylaxis of headaches in patients with Episodic Migraine (<15 headaches days per month).¹

BOTOX® for Chronic Migraine has not been evaluated in clinical trials beyond 5 injection cycles.¹

BOTOX® should only be given by physicians with the appropriate qualifications and experience in the treatment and the use of required equipment. Follow the recommended dosage and frequency of administration for BOTOX®.¹

Caution should be used when BOTOX® is used in the presence of inflammation at the proposed injection site(s) or when excessive weakness or atrophy is present in the target muscle.¹

Muscle weakness remote to the site of injection and other serious adverse effects (e.g. dysphagia, aspiration pneumonia) have been rarely reported in both pediatric and adult patients, in some cases associated with a fatal outcome.¹

Patients or caregivers should be advised to seek immediate medical care if swallowing, speech or respiratory disorders arise.¹

As with all biologic products, an anaphylactic reaction may occur. Necessary precautions should be taken and epinephrine should be available.¹

There have been rare reports following administration of botulinum toxin of adverse events involving the cardiovascular system, including arrhythmia and myocardial infarction, some with fatal outcomes. Some of these patients had risk factors including pre-existing cardiovascular disease. The exact relationship of these events to BOTOX®/BOTOX COSMETIC® is unknown.¹

There have been rare cases of administration of botulinum toxin to patients with known or unrecognized neuromuscular junction disorders where the patients have shown extreme sensitivity to the systemic effects of typical clinical doses. In some of these cases, dysphagia has lasted several months and required placement of a gastric feeding tube. When exposed to very high doses, patients with neurologic disorders, e.g. pediatric cerebral palsy or adult spasticity, may also be at increased risk of clinically significant systemic effects.¹

The discontinuation rate due to adverse events in these phase 3 trials was 3.8% for BOTOX® vs. 1.2% for placebo. The most frequently reported adverse events leading to discontinuation in the BOTOX® group were neck pain (0.6%), muscular weakness (0.4%), headache (0.4%), and migraine (0.4%).¹

1. BOTOX® Product Monograph, October 18, 2011.

 ALLERGAN

 PAAB

© 2011 Allergan Inc., Markham ON L6G 0B5

® Registered trademark of Allergan Inc.

 BOTOX®
onabotulinumtoxinA



see prescribing information pn pages A-15 to 17



* Fictitious patient. May not be representative of all fibromyalgia cases.



FACED WITH PAIN*

IN HER STRUGGLE WITH FIBROMYALGIA

First treatment indicated in Canada for adults for the management of pain associated with

fibromyalgia¹

Pregabalin: first-line treatment for chronic

neuropathic pain²

DEMONSTRATED SIGNIFICANT RELIEF IN PAIN AND PAIN-RELATED SLEEP DIFFICULTIES IN FIBROMYALGIA¹

Demonstrated powerful, rapid and sustained pain relief^{1,3-5}

In fibromyalgia:

- In a 14 week study, LYRICA demonstrated significant pain reduction as early as week 1 ($p < 0.05$ for all doses). Mean changes in pain scores at the end of the study for LYRICA-treated patients were significantly greater versus placebo (300 mg/day, $n=183$: -1.75, $p=0.0009$; 450 mg/day, $n=190$: -2.03, $p < 0.0001$; 600 mg/day, $n=188$: -2.05, $p < 0.0001$; placebo, $n=184$: -1.04)³
- In another study of 26 weeks' duration of patients who initially responded to LYRICA during a 6-week, open-label phase, 68% of those who continued on their optimized dose ($n=279$) maintained a treatment response versus 39% of those on placebo ($n=287$). The time to loss of therapeutic response was longer in the LYRICA group ($p < 0.0001$)⁴

Also in neuropathic pain (NeP):

- Sustained pain relief (starting at week 2 for LYRICA 150-600 mg/day, $n=141$; $p < 0.05$ vs placebo, $n=65$) was demonstrated throughout a 12 week study in patients with DPN or PHN⁵

Demonstrated effective in relieving pain-related sleep difficulties^{1,6}

In fibromyalgia:

- In a 13 week study, LYRICA reduced overall MOS-Sleep Scale scores significantly more at the end of the study vs. placebo (300 mg/day -19.1, $p=0.0174$; 450 mg/day: -20.41, $p=0.0026$; 600 mg/day: -19.49, $p=0.0101$; placebo: -14.29)⁶

Also in NeP:

- LYRICA reduced sleep disturbances across several studies in DPN and PHN, of 8-12 weeks duration¹

Flexible dosing across all indications^{1†}

LYRICA (pregabalin) is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN), postherpetic neuralgia (PHN) and spinal cord injury in adults. LYRICA may be useful in the management of central neuropathic pain in adults. LYRICA is indicated for the management of pain associated with fibromyalgia in adults. The efficacy of LYRICA in the management of pain associated with fibromyalgia for up to 6 months was demonstrated in a placebo-controlled trial in patients who had initially responded to LYRICA during a 6-week open-label phase.

LYRICA is contraindicated in patients who are hypersensitive to pregabalin or to any ingredient in the formulation or component of the container.

The most commonly observed adverse events ($\geq 5\%$ and twice the rate as that seen with placebo) in the recommended dose range of 150 mg/day to 600 mg/day in PHN and DPN patients were: dizziness (9.0-37.0%), somnolence (6.1-24.7%), peripheral edema (6.1-16.2%), and dry mouth (1.9-14.9%) and were dose related; in spinal cord injury patients: somnolence (41.4%), dizziness (24.3%), asthenia (15.7%), dry mouth (15.7%), edema (12.9%), constipation (12.9%), amnesia (10.0%), myasthenia (8.6%), amblyopia (8.6%), and thinking abnormal (8.6%); in fibromyalgia patients: dizziness (37.5%), somnolence (18.6%), weight gain (10.6%), dry mouth (7.9%), blurred vision (6.7%), and peripheral edema (6.1%). In LYRICA-treated fibromyalgia patients, the most commonly observed dose-related adverse events were: dizziness (22.7-46.5%), somnolence (12.9-20.7%), weight gain (7.6-13.7%), peripheral edema (5.3-10.8%). The most commonly observed adverse events in the PHN, DPN, spinal cord injury and fibromyalgia patients were usually mild to moderate in intensity. Discontinuation rates due to adverse events for LYRICA and placebo, respectively, were 9% and 4% in DPN, 14% and 7% in PHN, 21% and 13% in spinal cord injury, and 20% and 11% in fibromyalgia. There was a dose-dependent increase in rate of discontinuation due to adverse events in fibromyalgia.

There have been post-marketing reports of angioedema in patients, some without reported previous history/episodes, including life-threatening angioedema with respiratory compromise. Caution should be exercised in patients with previous history/episodes of angioedema and in patients who are taking other drugs associated with angioedema.

In clinical trials and in post-marketing experience, there have been reports of patients, with or without previous history, experiencing renal failure alone or in combination with other medications. Caution is advised when prescribing to the elderly or those with any degree of renal impairment.

There have been post-marketing reports of events related to reduced lower gastrointestinal tract function (e.g., intestinal obstruction, paralytic ileus, and constipation) in patients, some without reported previous history/episode(s), during initial/acute and chronic treatment with LYRICA, primarily in combination with other medications that have the potential to produce constipation. Some of these events were considered serious and required hospitalization. In a number of instances, patients were taking opioid analgesics including tramadol. Caution should be exercised when LYRICA and opioid analgesics are used in combination, and measures to prevent constipation may be considered, especially in female patients and elderly as they may be at increased risk of experiencing lower gastrointestinal-related events.

Dosage reduction is required in patients with renal impairment (creatinine clearance <60 mL/min) and in some elderly patients as LYRICA is primarily eliminated by renal excretion.

Please see Prescribing Information for complete Warnings and Precautions, Adverse Reactions, Dosage and Administration and patient selection criteria.

† Please consult Prescribing Information for complete Dosage and Administration instructions.



Working together for a healthier world™

©2010
Pfizer Canada Inc.
Kirkland, Quebec
H9J 2M5

™Pfizer Inc, used under license
LYRICA® C.P. Pharmaceuticals International C.V.,
owner/Pfizer Canada Inc., Licensee



See prescribing information and study parameters on pages A-13, A-14

Editor-in-Chief/Rédacteur en chef

G. Bryan Young LONDON, ON

Associate Editors/Rédacteurs associés

J. Max Findlay EDMONTON, AB
Michael Shevell MONTREAL, QC
Timothy J. Benstead HALIFAX, NS
Mike Poulter LONDON, ON
Serge Gauthier VERDUN, QC
Robert Hammond LONDON, ON

Past Editors/Anciens rédacteurs en chef

Douglas W. Zochodne CALGARY, AB
James A. Sharpe TORONTO, ON
Robert G. Lee CALGARY, AB
Robert T. Ross WINNIPEG, MB
(Emeritus Editor, Founding Editor)

Editorial Board/Conseil d'éditorial

Jorge Burneo LONDON, ON
Richard Desbiens QUEBEC CITY, QC
David Fortin SHERBROOKE, QC
Mark Hamilton CALGARY, AB
Hans-Peter Hartung DUSSELDORF, GERMANY
Michael Hill CALGARY, AB
Alan C. Jackson WINNIPEG, MB
Daniel Keene OTTAWA, ON
Terence Myles CALGARY, AB
James Perry TORONTO, ON
Oksana Suchowersky CALGARY, AB
Brian Toyota VANCOUVER, BC
Brian Weinschenker ROCHESTER, MN, USA
Samuel Wiebe CALGARY, AB
Elaine Wirrell ROCHESTER, MN, USA

SECTION EDITORS/CONSEIL DE RÉDACTION

Neuroimaging Highlight/Neuroimagerie

David Pelz LONDON, ON

Neuropathological Conference/Conférence sur la neuropathologie

Robert Hammond LONDON, ON

**Book Review/Critiques de livres
Reflections/Reflets**

Andrew Kirk SASKATOON, SK

**Critically Appraised Topic Summaries
(CATS)**

Jorge Burneo LONDON, ON
Mary Jenkins LONDON, ON

**Editorial Review Board/Conseil de
Revue d'éditorial**

Donald Brunet KINGSTON, ON
Jodie Burton CALGARY, AB
Lionel Carmant MONTREAL, QC
Colin Chalk MONTREAL, QC
K. Ming Chan EDMONTON, AB
Robert Chen TORONTO, ON
Mary Connolly VANCOUVER, BC
Joseph Dooley HALIFAX, NS
Paolo Federico CALGARY, AB
Daryl Fournay SASKATOON, SK
Hannah Glass SAN FRANCISCO, CA, USA
Alan Goodridge ST. JOHN'S, NL
Ian Grant HALIFAX, NS
Alan Guberman OTTAWA, ON
John Hurlbert CALGARY, AB
Manouchehr Javidan VANCOUVER, BC
Patrick McDonald WINNIPEG, MB
Martin McKeown VANCOUVER, BC
Joseph Megyesi LONDON, ON
Vivek Mehta EDMONTON, AB
Steven Miller VANCOUVER, BC
Neelan Pillay CALGARY, AB
Christopher Power EDMONTON, AB
Alex Rajput SASKATOON, SK
Jean Raymond MONTREAL, QC
Gary Redekop VANCOUVER, BC
Mark Sadler HALIFAX, NS
Harvey Sarnat CALGARY, AB
John Stewart VANCOUVER, BC
Jeanne Teitelbaum MONTREAL, QC
Eve Tsai OTTAWA, ON
Shannon Venance LONDON, ON
Matt Wheatley EDMONTON, AB
Jerome Yager EDMONTON, AB

Journal Staff - Calgary, AB

Dan Morin, *Chief Executive Officer*
Maggie McCallion, *Designer/*
Production Coordinator
Cindy Leschyshyn, *Editorial Coordinator*

**Advertising representative/Représentant de
publicité:**

Brett Windle
Corporate Development Coordinator
Tel (403) 229-9575 Fax (403) 229-1661
E-mail: brett-windle@cnsfederation.org

Printer/Imprimeur:

Unicom Graphics, 4501 Manitoba Road SE
Calgary, Alberta T2G 4B9

The official journal of: / La Revue officielle de:

**The Canadian Neurological Society
La Société Canadienne de Neurologie**

**The Canadian Neurosurgical Society
La Société Canadienne de Neurochirurgie**

**The Canadian Society of Clinical Neurophysiologists
La Société Canadienne de Neurophysiologie Clinique**

**The Canadian Association of Child Neurology
L'Association Canadienne de Neurologie Pédiatrique**

The permanent secretariat for the four societies and the Canadian Neurological Sciences Federation is at:
Le secrétariat des quatre associations et du Fédération des sciences neurologiques du Canada est situé en permanence à:

7015 Macleod Trail SW, Suite 709
Calgary, Alberta, Canada T2H 2K6
CNSF (403) 229-9544 / CJNS (403) 229-9575
Fax (403) 229-1661

The Canadian Journal of Neurological Sciences is published bi-monthly. The annual subscription rate for Individuals (print and online) are: C\$170.00 (Canada), C\$200.00 (US), C\$280.00 (International). Subscription rates for Institutions (print and online) are C\$190.00 (Canada), C\$220.00 (US), C\$300.00 (International). "Online Only" - Available only to International subscribers - C\$160.00 (Individual), C\$180.00 (Institutional). See www.cjns.org for full details including taxes. Single copies C\$30.00 each plus C\$25.00 shipping and handling. E-mail: journal@cjns.org. COPYRIGHT © 2012 by THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. All rights reserved. No part of this journal may be reproduced in any form without the prior permission of The Canadian Journal of Neurological Sciences. Postage paid at Calgary, Alberta.

Le Journal canadien des sciences neurologiques est publié tous les deux mois. Voici les prix d'abonnement pour les personnes (imprimé et en ligne) : 170,00 \$ C (Canada), 200,00 \$ C (É.-U.), 280,00 \$ C (international). Voici les prix d'abonnement pour les institutions (imprimé et en ligne) : 190,00 \$ C (Canada), 220,00 \$ C (É.-U.), 300,00 \$ C (international). « En ligne seulement » (offre seulement aux abonnés internationaux) : 160,00 \$ C (personnes), 180,00 \$ C (institutions). Visitez www.cjns.org pour tous les détails incluant les taxes. Exemplaires uniques : 30,00 \$ C l'unité, plus 25,00 \$ C en frais de port et de manutention. Courriel : journal@cjns.org. COPYRIGHT © 2012 du THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. Tous droits réservés. Aucune partie de ce journal ne peut être reproduite sous quelque forme que ce soit sans la permission préalable du Journal de la Fédération des sciences neurologiques du Canada. Frais de port payés à Calgary, en Alberta.


This journal is indexed by / Cette Journal est cité et indexé dans: *Adis International, ArticleFirst, BIOBASE, BioAb, BioSci, BIOSIS Prev, Centre National de la Recherche Scientifique, CSA, CurAb, CurCont, De Gruyter Saur, E-psyche, EBSCO, Elsevier, EMBASE, FRANCIS, IBZ, Internationale Bibliographie der Rezensionen Geistes- und Sozialwissenschaftlicher Literatur, MEDLINE, MetaPress, National Library of Medicine, OCLC, PE&ON, Personal Alert, PsycFIRST, PsycINFO, PubMed, Reac, RefZh, SCI, SCOPUS, Thomson Reuters, TOCpre, VINITI RAN, Web of Science.*

ISSN 0317 - 1671



Richness is:

Having a vast universe to explore



You define richness. With the *Scotia Professional*[®] Plan, we can help with the money part. You've worked long and hard to build your career. It only makes sense to do everything you can to ensure your continued success, both professionally and personally. The Professional Plan is a fully customized banking package designed to help you build a strong, profitable business while ensuring your personal finances receive the attention they deserve. Which gives you more time to explore the universe within.

To learn more about *Scotia Professional* Plan, visit your nearest Scotiabank branch or visit scotiabank.com/professional today.

Scotia Professional Plan

You're richer than you think!





VIMPAT® (lacosamide) is indicated as adjunctive therapy in the management of partial-onset seizures in adult patients with epilepsy (≥ 18 years of age) who are not satisfactorily controlled with conventional therapy. The clinical experience with VIMPAT® in elderly patients with epilepsy (≥ 65 years of age) is limited. Caution should be exercised during dose titration and age-associated decreased renal clearance should be considered in elderly patients. The safety and efficacy of VIMPAT® in pediatric patients (< 18 years of age) have not been established and its use in this patient population is not indicated.

VIMPAT® is contraindicated in patients who are hypersensitive to the active substance or to any of the excipients and in patients with a history of, or presence of, second- or third-degree atrioventricular (AV) block.

Second degree or higher AV block has been reported in post-marketing experience. Patients should be made aware of the symptoms of second-degree or higher AV block (e.g. slow or irregular pulse, feeling of lightheadedness and fainting), and told to contact their physician should any of these symptoms occur. VIMPAT® should be used with caution in patients with known conduction problems (e.g. marked first-degree AV block, sick sinus syndrome without pacemaker), or with a history of severe cardiac disease such as myocardial ischemia or heart failure. In such patients, obtaining an ECG before beginning VIMPAT®, and after VIMPAT® is titrated to steady-state, is recommended. Caution should especially be exerted when treating elderly patients as they may be at increased risk of cardiac disorder or when VIMPAT® is given with other drugs that prolong the

PR interval (e.g. carbamazepine, pregabalin, lamotrigine, beta-blockers, and class I antiarrhythmic drugs), as further PR prolongation is possible. In clinical trials of healthy subjects and patients with epilepsy, VIMPAT® treatment was associated with PR interval prolongation in a dose-dependent manner. VIMPAT® administration may predispose to atrial arrhythmias (atrial fibrillation or flutter), especially in patients with diabetic neuropathy and/or cardiovascular disease. Patients should be made aware of the symptoms of atrial fibrillation and flutter (e.g. palpitations, rapid or irregular pulse, shortness of breath) and told to contact their physician should any of these symptoms occur. Atrial fibrillation and flutter have been reported in open-label epilepsy trials and in postmarketing experience.

Multiorgan hypersensitivity reactions (also known as Drug Rash with Eosinophilia and Systemic Symptoms, or DRESS), Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) have been reported with anticonvulsants. If any of these hypersensitivity reactions are suspected, VIMPAT® should be discontinued and alternative treatment started.

Treatment with VIMPAT® has been associated with dizziness and ataxia, which could increase the occurrence of accidental injury or falls. Accordingly, patients should be advised not to drive a car or to operate other complex machinery or perform hazardous tasks until they are familiar with the effects of VIMPAT® on their ability to perform such activities.

In controlled trials in patients with partial-onset seizures, VIMPAT® treatment was associated with vision-related adverse events such as blurred vision and diplopia. Patients should be informed



VIMPAT® is a registered trademark used under license from Harris FRC Corporation. VIMPAT logo™ is a trademark used under license from Harris FRC Corporation. UCB The Epilepsy Company® is a registered trademark of the UCB Group of Companies. © 2012, UCB Canada Inc. All rights reserved. VIM-12-173 Date of preparation: March 2012

When seizure control is still an issue for your patient

Bring VIMPAT[®] into the picture

Efficacy in patients inadequately controlled on 1 to 3 AEDs*†1

- ◆ Significant median **36-39% reduction in seizure frequency** per 28 days from baseline to maintenance phase*1
 - ◆ VIMPAT[®] 400 mg/day vs. placebo: Ben-menachem, *et al.* (39% vs. 10%, $p \leq 0.01$); Chung, *et al.* (37.3% vs. 20.8%, $p \leq 0.01$); Halász, *et al.* (36.4% vs. 20.5%, $p \leq 0.05$)*1

Generally well tolerated when added to common concomitant therapy

- ◆ Some of the most frequently reported **adverse reactions** with VIMPAT[®] 400 mg/day were dizziness (30%), nausea (11%), and vision-related events, including diplopia (10%) and blurred vision (9%)

The recommended starting dose for VIMPAT[®] is 50 mg twice a day which should be increased to an initial therapeutic dose of 100 mg twice a day after one week. Depending on patient response and tolerability, the maintenance dose of VIMPAT[®] can be increased by 50 mg twice daily every week, to a **maximum recommended dose of 400 mg/day**.¹

Please consult product monograph for complete dosing and administration instructions.

POWER for added control.

that if visual disturbances occur, they should notify their physician promptly. If visual disturbance persists, further assessment, including dose reduction and possible discontinuation of VIMPAT[®], should be considered.

More frequent assessments should be considered for patients with known vision-related issues or those who are already routinely monitored for ocular conditions.

Suicidal ideation and behaviour have been reported in patients treated with antiepileptic agents in several indications. All patients treated with antiepileptic drugs, irrespective of indication, should be monitored for signs of suicidal ideation and behaviour and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge.

There are no studies with VIMPAT[®] in pregnant women. Since the potential risk for humans is unknown, VIMPAT[®] should not be used during pregnancy unless the benefit to the mother clearly outweighs the potential risk to the foetus. It is unknown whether VIMPAT[®] is excreted in human breast milk. Because many drugs are excreted into human milk, a decision should be made whether to discontinue nursing or to discontinue VIMPAT[®], taking into account the importance of the drug to the mother.

As with all antiepileptic drugs, VIMPAT[®] should be withdrawn gradually (over a minimum of 1 week) to minimize the potential of increased seizure frequency.

In controlled clinical trials in patients with partial-onset seizures, some of the most frequently

reported adverse reactions with VIMPAT[®] treatment were dizziness (16% and 30% for 200 mg and 400 mg treatment groups, respectively, vs. 8% placebo), nausea (7% and 11% vs. 4%), and vision related events [diplopia (6% and 10% vs. 2%) and blurred vision (2% and 9% vs. 3%)]. They were dose-related and usually mild to moderate in intensity. The adverse events most commonly leading to discontinuation were dizziness, coordination abnormal, vomiting, diplopia, nausea, vertigo, and vision blurred.

Please see the VIMPAT[®] Product Monograph for full prescribing information.

* 3 randomized, double-blind, placebo-controlled, multicentre trials studying VIMPAT[®] (lacosamide) as adjunctive therapy in adult patients with POS with or without secondary generalization. In the studies, patients were to have been taking a stable dosage regimen of one to three AEDs, with or without vagal nerve stimulation in the 4 weeks before enrollment and during the baseline period. Following the 8-week baseline phase, subjects were randomized and up-titrated by initiating treatment of 100 mg/day, and increased in weekly increments of 100 mg/day to the target dose. The titration phase lasted 4-6 weeks. Patients then entered a 12-week maintenance phase period.^{1,2,4}

† AED=anti-epileptic drug

References: 1. VIMPAT[®] Product Monograph, UCB Canada Inc., October 6, 2011. 2. Ben-Menachem E, Biton V, Jatzisz D, *et al.* Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. *Epilepsia* 2007; 48(7):1308-1317. 3. Chung S, Sperling MR, Biton V *et al.* Lacosamide as adjunctive therapy for partial onset seizures: A randomized controlled trial. *Epilepsia* 2010; 51(6):958-967. 4. Halász P, Kälviainen R, Mazankiewicz-Baldzińska M, *et al.* Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. *Epilepsia* 2009; 50(3):443-453.



POWER for Added Control



Board of Directors and Committee Chairs

The Canadian Neurological Sciences Federation (CNSF) and
The Neurological Sciences Foundation of Canada (NSFC)



John Stewart
CNSF/NSFC President
CNS & CSCN Member



J. Max Findlay
CNSF/NSFC Vice-President
CNSS Member



Jeanne Teitelbaum
CNSF/NSFC Vice-President
CNS Member



Garth Bray
CNSF/NSFC Vice-President
CNS Member



Sharon Whiting
CNSF/NSFC Board
CACN President



Narayan Prasad
CNSF/NSFC Board
CACN Vice-President



Chris Wallace
CNSF/NSFC Board
CNSS President



Brian Toyota
CNSF/NSFC Board
CNSS Vice-President



Sarah Kirby
CNSF/NSFC Board
CNS President



Jason Barton
CNSF/NSFC Board
CNS Vice-President



Seyed Mirsattari
CNSF/NSFC Board
CSCN President



Kristine Chapman
CNSF/NSFC Board
CSCN Vice-President



Jennifer Gelinas
CNSF/NSFC Board
Residents' Rep. CACN



Roberto Diaz
CNSF/NSFC Board
Residents' Rep. CNSS



Laine Green
CNSF/NSFC Board
Residents' Rep. CNS



Michael Hill
CNSF/NSFC Board
Member-At-Large



Chris Ekong
CNSF/NSFC Board
Member-At-Large



Derek Fewer
CNSF/NSFC Past President
CNSS Member



Dan Morin
CNSF/NSFC Board
CEO




G. Bryan Young
Journal Editor-in-Chief
CNS & CSCN Member



R. Loch Macdonald
CNSF SPC Chair
CNSS Member



Ron Prokrupa
CNSF PDC Chair
CNSS Member



George Elleker
CPGC Chair
CNS & CSCN Member



Richard Riopelle
CBANHC Chair
CNS Member



Morris Freedman
IDC Chair
CNS Member